


Utilizing Skyline in Automated System Suitability Testing, Data QC, and Metabolite Quantification for Microchip CE-MS Analysis

Sam Stewart, Erin Redman, J. Will Thompson Research and Development, 908 Devices Inc.

Metabolomics with ZipChip (microchip CZE-MS)


EXTRACTION

20 uL sample 140 uL MeOH+IS 40 uL Ammon. Acetate





×908 devices

mCE-HRMS



TARGETED QUANT





Areas we are utilizing **Skyline** in our software pipeline

System Suitability

Data Quality Check

Quantification



Before Data Collection




Immediately After Data Collection



Post-Analysis




Areas we are Utilizing Skyline in our Software Pipeline





How we interact with Skyline (SST and Data Check)



For our Product, **Skyline** Provides:

- Template/Library for Compounds
- Raw Data Access/Peak Extraction
- Raw Data Visualization (as desired... "White Box")



System Suitability in Mass Spectrometry 'Omics





FIG. 1. Schematic representation of performance metrics mapped to LC-MS/MS system elements. *PW*, peak width; *IQ*, interquartile; *pep*, peptide; *ID*, identification; *Med.*, median; *ID'd*, identified; *Fract.*, fraction; *Num.*, number.

Rudnick PA et al. *Mol Cell Proteomics.* **2010** Feb;9(2):225-41.

Bereman et al.: Statistical Process Control for Proteomics



Bereman et al. J Am Soc Mass Spectrom. 2014 Apr;25(4):581-7.

System Suitability in Mass Spectrometry 'Omics





FIG. 1. Schematic representation of performance metrics mapped to LC-MS/MS system elements. *PW*, peak width; *IQ*, interquartile; *pep*, peptide; *ID*, identification; *Med.*, median; *ID'd*, identified; *Fract.*, fraction; *Num.*, number.

Rudnick PA et al. Mol Cell Proteomics. 2010 Feb;9(2):225-41.

Bereman et al.: Statistical Process Control for Proteomics



Bereman et al. J Am Soc Mass Spectrom. 2014 Apr;25(4):581-7.

Key Issues:

- 1. There are too many possible **metrics**
- 2. Reference **ranges** are difficult to establish

We should:

- 1. Pick the **simplest** set of metrics that work
- 2. Pick **fixed** threshold/cutoffs if we can




System Suitability Testing – Importance of Automation

Ready




1/1 list 4/5 mol 4/5 prec 7/10 tran






mCZE System Suitability Testing – Integration with Skyline





Skyline Template for Extracting Chromatograms 350 300 250 Intensity (10^6) 200 150 100 50 0 3 4 5 2 Retention Time 5 analytes, 4 m/z values ZipChip HR, Peptides BGE Exploris 240 MS

10 uM Promega AA Mix




ZipChip ACE RM system suitability test (SST) is complete and has passed with the following scores. Please proceed with your sample analysis. If samples are not analyzed within 4 hours, we recommend repeating SST before initializing ZipChip ACE RM sample set.


Resolution: 1.80, Bounds: [1.25, inf], Status: Passed. BGE Quality: 0.28, Bounds: [0.0, 0.5], Status: Passed. Lysine Migration Time (minutes): 2.91, Bounds: [2.5, 3.6], Status: Passed. Aspartate Migration Time (minutes): 6.03, Bounds: [2.5, 8.0], Status: Passed.



Data Check Standard Practice: Manual Data "Check"



"Data Check" Acceptance Criteria







"Data Check" Acceptance Criteria

File										30		ak Area			
Experiment Options		Experiment Info	Analysis Options			Reporting Option			- 61						
Kit ID	HR007629	Sample Count	23 Analysis Template		Browse	Exclude Analytes	vith % Missing Data					•			
Sample List	:essing_ACEDemo_011624.csv Brows	Total Runs in Experim Wells Remaining	ent 37 5 Skyline Migration	ime Library	Browse	Exclude Analytes	vith % CV of SPQC								
Project ID	IQX	Total Time	7h:24m Custom Report Fo		itative ~			View Report							
MS Serial Number	IQX_01		Extra Custom Out			-						•			
ZC Serial Number	ZLA123		Bias of Calibration SST Status	Points to Exclude 20% Passed								•			
ZCI Run Time Include a Study Pool QC (S	11.0		File Check Status	Passed Must R										- 9	
Number of Analyses	(SPQC)/	-	Failed Data Check	1					•		• •	•••			•
Interleave Groups?			Passed Data Chec								••••	•	•	• • •	
Instrument Type	Thermo				ocess SST Data Check							•		•	
Starting Well Location	A1			Proce	ess Samples 908 AI						• • •				
Replicates Per Sample	The 7's Cl !	CE III I				1						•	•		-
Experiment Folder					our runs appear to							-		-	-
MS Method	been missed in	njections. These	runs have been ar	notated in yo	our run list and a ne	ew run list							(•	
			the samples that s												
Sample Laugut	nus seen enpe														
Sample Layout		-							- L.						
Sample Layout Empty Well:		-			collect Ignore I	Bad Runs									
Empty Well:					collect Ignore I		Filename		^						_
Empty Well:	0000000		Human Serum (Re-	VSRM-0000351, Lot HMN1211904	B2 2024	0116_121031_IQX_01_HR007629	9_B2_HumanSerum_04_13		•					
Empty Well:	0000000		Human Serum (Human Serum)	ender Pooled, PN HUMAN	NSRM-0000351, Lot HMN1211904	B2 2024 C2 2024	0116_121031_IQX_01_HR007629 0116_121031_IQX_01_HR007629	9_B2_HumanSerum_04_13 9_C2_HumanSerum_05_14		40		60		80	
Empty Well:	0000000			ender Pooled, PN HUMAN ander Pooled, PN HUMAN ender Pooled, PN HUMAN	VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904	B2 2024 C2 2024 D2 20244	0116_121031_IQX_01_HR007629 0116_121031_IQX_01_HR007629 0116_121031_IQX_01_HR007629	9_B2_HumanSerum_04_13 9_C2_HumanSerum_05_14 9_D2_HumanSerum_06_15	5	40				80	
Empty Well:			Human Plasma	Ree ender Pooled, PN HUMAN ender Pooled, PN HUMAN ender Pooled, PN HUMAN 22DTA Gender Pooled He	VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 NSRM-0000351, Lot HMN1211904 at Inactivated, PN HUMANPLK2-012	B2 2024 C2 2024 D2 2024 22691 E2 2024	1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629	9_B2_HumanSerum_04_13 9 <mark>_C2_HumanSerum_05_14</mark> 9_D2_HumanSerum_06_15 9_E2_HumanPlasma_01_16	5 6	40	tion	60 Numbe		80	
Empty Well:	0000000		Human Plasma	Ree ender Pooled, PN HUMAN ender Pooled, PN HUMAN ender Pooled, PN HUMAN 22DTA Gender Pooled He	VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904	B2 2024 C2 2024 D2 2024 22691 E2 2024	0116_121031_IQX_01_HR007629 0116_121031_IQX_01_HR007629 0116_121031_IQX_01_HR007629	9_B2_HumanSerum_04_13 9 <mark>_C2_HumanSerum_05_14</mark> 9_D2_HumanSerum_06_15 9_E2_HumanPlasma_01_16	5 6	40	tion			80	
Empty Well 1 2 3 A 0 0 0 0 0 B 0 0 0 0 C 0 0 0 0 D 0 0 0 0			Human Plasma Human Plasma	Ree ender Pooled, PN HUMAN ender Pooled, PN HUMAN ender Pooled, PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled He	VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 NSRM-0000351, Lot HMN1211904 at Inactivated, PN HUMANPLK2-012	B2 2024 C2 2024 D2 2024 22691 E2 2024 22691 F2 2024	1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629	9_82_HumanSerum_04_13 9_C2_HumanSerum_05_14 9_D2_HumanSerum_06_15 9_E2_HumanPlasma_01_16 9_F2_HumanPlasma_02_17	5 6 7	40	tion			80	
Empty Well 1 2 3 A 0 0 0 0 0 B 0 0 0 0 C 0 0 0 0 0 E 0 0 0 0 0 E 0 0 0 0 0			Human Plasma Human Plasma	Ree ender Pooled, PN HUMAN ender Pooled, PN HUMAN ender Pooled, PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled He	VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012	B2 2024 C2 2024 D2 2024 22691 F2 2024 22691 G2 2024 22691 G2 2024	1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629	9_82_HumanSerum_04_13 9_02_HumanSerum_05_14 9_02_HumanSerum_06_15 9_E2_HumanPlasma_01_16 9_F2_HumanPlasma_02_17 9_G2_HumanPlasma_03_18	5 6 7	40	tion			80	
Empty Well			Human Plasma Human Plasma Human Plasma	Ree ender Pooled, PN HUMAN ender Pooled, PN HUMAN ender Pooled, PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled He	VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012	B2 2024 C2 2024 D2 2024 22691 E2 2024 22691 F2 2024 22691 F1 2024	1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629	9, 82, HumanSerum, 04, 13 9, 02, HumanSerum, 05, 14 9, 02, HumanSerum, 06, 15 9, 62, HumanPlasma, 01, 16 9, 62, HumanPlasma, 02, 17 9, 62, HumanPlasma, 03, 18 9, 61, SPQC, 19	5 6 7	40	tion			80	
Empty Well			Human Plasma Human Plasma Human Plasma nan	Ree ender Pooled, PN HUMAN ender Pooled, PN HUMAN ender Pooled, PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled He	VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012	B2 2024 C2 2034 D2 2034 D2 2024 22691 E2 2024 22691 G2 2024 22691 F2 2024 22691 G2 2024 P1 2024 2024	116_121031_IQX_01_HR007629 116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629 1116_121031_IQX_01_HR007629	9, 82, HumanSerum, 04, 13 120, HumanSerum, 05, 14 9, 02, HumanSerum, 06, 15 9, 62, HumanPlasma, 01, 16 9, 72, HumanPlasma, 03, 18 9, 61, SPQC, 19 9, 01, DQCLow, 20	5 6 7	40	tion			80	
Empty Well 1 2 3 A C C C C C C C C C C			Human Plasma Human Plasma Ruman Plasma nan nan nan	ender Pooled, PN HUMAN Inder Pooled, PN HUMAN ender Pooled, PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled He 2EDTA Gender Pooled He	VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 VSRM-0000351, Lot HMN1211904 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012	B2 2024 D2 2024 D1 2024 D1 2024 D1 2024 D1 2024 D1 2024	H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629	9,82,HumanSerum_04,13 20,22HumanSerum_05,14 9,02,HumanSerum_06,15 9,62,HumanPlasma_01,16 9,72,HumanPlasma_02,17 9,62,HumanPlasma_03,18 9,F1_SPQC_19 9,01,QCLow_20 9,61,QCHigh_21	5 6 7 8	40	tion			80	
Empty Welt 1 2 3 A 3 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6			Human Plasma Human Plasma nan nan Human Plasma	Ree ender Pooled. PN HUMAN mder Pooled. PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled He 2EDTA Gender Pooled He	SRM-0000351, Eot HIMIN1211904 SRM-0000351, Eot HIMIN1211904 USRM-0000351, Lot HIMIN1211904 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012	B2 2024 B2 2024 D2 2024 D1 2024 D1 2024 D1 2024 D2 2024 D1 2024 D1 2024 D2 2024	H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629	9,82,HumanSerum_04,13 20,22HumanSerum_05,14 9,02,HumanSerum_06,15 9,62,HumanPlasma_01,16 9,72,HumanPlasma_02,17 9,62,HumanPlasma_03,18 9,61,SPQC_19 9,01,QCLow_20 9,61,QCHigh_21 9,12,HumanPlasma_04,22	5 6 6 7 7 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	40	tion			80	
Empty Welt 1 2 3 A 3 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6			Human Plasma Human Plasma nan nan Human Plasma Human Plasma Human Plasma	Ree ender Pooled, PN HUMAN meder Pooled, PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled He 2EDTA Gender Pooled He 2EDTA Gender Pooled He	SRM-0000351, Eot HIMN1211904 SRM-0000351, Eot HIMN1211904 USRM-0000351, Lot HIMN1211904 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012	B2 2024 B2 2024 D2 2024 D1 2024 D2 2024 D1 2024 D1 2024 D2 2024 D2 2024 D2 2024 D1 2024 D2 2024	H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629	9,82,HumanSerum_04,13 9,02,HumanSerum_06,15 9,22,HumanPlasma_01,16 9,72,HumanPlasma_02,17 9,62,HumanPlasma_03,18 9,71,SPQC_19 9,01,QCLow_20 9,61,QCHigh_21 9,14,HumanPlasma_04,22 9,A3,HumanPlasma_05,23	2	40	tion			80	
Empty Welt 1 2 3 A 3 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6			Human Plasma Human Plasma nan nan Human Plasma Human Plasma Human Plasma	Ree ender Pooled, PN HUMAN meler Pooled, PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled He 2EDTA Gender Pooled He 2EDTA Gender Pooled He 2EDTA Gender Pooled He	SRM-0000351, EOF HMN1211904 SRM-0000351, EOF HMN1211904 Ast Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012	B2 2024 D2 2024 D1 2024 D1 2024 D1 2024 D2 2024 D1 2024 D1 2024 D2 2024 D1 2024 D2 2024	H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629	9,82,HumanSerum,04,13 9,02,HumanSerum,05,14 9,02,HumanPlasma,01,16 9,72,HumanPlasma,02,17 9,62,HumanPlasma,02,17 9,62,HumanPlasma,03,18 9,11,SPQC_19 9,01,QCLow,20 9,61,QCHigh,21 9,14,HumanPlasma,04,22 9,A3,HumanPlasma,05,23 9,B3,HumanPlasma,06,24	2	40	tion			80	
Empty Welt 1 2 3 A 3 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6			Human Plasma Human Plasma nan nan Human Plasma Human Plasma Human Plasma Human Plasma	Ree ender Pooled, PN HUMAN mehr Pooled, PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled He	SKM-0000357, EOF HMN1211904 SKM-0000351, EOF HMN1211904 Astmanus (2000351, EOF HMN1211904 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012	B2 2024 D2 2024 D2 2024 D2 2024 E2 2024 E2 2024 E2 2024 E2 2024 E2 2024 E1 2024 E2 83 E3 2024 E3 2024 E3 2024 E3 2024 E3 2024 E3 2024	H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629	9,82,HumanSerum,04,13 9,02,HumanSerum,06,15 9,22,HumanPlasma,01,16 9,72,HumanPlasma,02,17 9,62,HumanPlasma,02,17 9,62,HumanPlasma,03,18 9,11,SPQC_19 9,01,QCLow,20 9,11,QCLigh,21 9,14,HumanPlasma,04,22 9,A3,HumanPlasma,05,23 9,83,HumanPlasma,06,24 9,G3,HumanUrine,01,25	5 6 7 8 8 2 3 4	40	tion			80	
Empty Well			Human Plasma Human Plasma nan nan Human Plasma Human Plasma Human Plasma Human Urine, S Human Urine, S	Ree ander Pooled, PN HUMAN ander Pooled, PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled He	SRM-0000351, EGF HMN1211904 SRM-0000351, EGF HMN1211904 Astman 2000351, EGF HMN1211904 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012 9/2023	B2 2024 D2 2024 D2 2024 D2 2024 E2 2024 E2 2024 E2 2024 E2 2024 E2 2024 E1 2024 E2 E3 2024 E2 E3 2024 E3 E3 2024 E3 E3 2024 E3 E3 2024 E3 E3 2024	H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629	9,82,HumanSerum,04,13 9,02,HumanSerum,06,15 9,02,HumanPlasma,01,16 9,72,HumanPlasma,02,17 9,62,HumanPlasma,03,18 9,71,SPQC_19 9,01,QCLow,20 9,61,QCHigh,21 9,14,HumanPlasma,04,22 9,A3,HumanPlasma,05,23 9,83,HumanPlasma,06,24 9,G3,HumanPlasma,06,24 9,G3,HumanUrine,01,25 9,D3,HumanUrine,02,26	5 6 7 8 8 2 3 4	40	tion			80	
Empty Welt 1 2 3 A 3 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6			Human Plasma Human Plasma nan nan Human Plasma Human Plasma Human Plasma Human Virie, S Human Urire, S Human Urire, S	Ree ander Pooled, PN HUMAN ander Pooled, PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled Hi 2EDTA Gender Pooled He 2EDTA Gender Pooled He 2EDTA Gender Pooled He 2EDTA Gender Pooled He	SISM-0000351; LOF HMN1211904 SISM-0000351; LOF HMN1211904 SISM-0000351; LOF HMN1211904 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012 9/2023 9/2023	B2 2024 D2 2024 D1 2024 P1 2024 D1 2024 D2 2024 D1 2024 D1 2024 D1 2024 D1 2024 D2 2024 D1 2024 D2 2024 D1 2024 D2 2024 D3 2024 D3 2024 D3 2024 D3	H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629	9,82,HumanSerum,04,13 9,02,HumanSerum,06,15 9,02,HumanPlasma,01,16 9,02,HumanPlasma,02,17 9,02,HumanPlasma,04,21 9,01,QCLow,20 9,01,QCL	5 6 7 8 8 2 3 4	40	tion			80	
Empty Well			Human Plasma Human Plasma nan nan Human Plasma Human Plasma Human Plasma Human Virie, S Human Urire, S Human Urire, S Human Urire, S	Ree ander Pooled, PN HUMAN ander Pooled, PN HUMAN 2EDTA Gender Pooled He 2EDTA Gender Pooled He	ASKM-0000351, EAF HMN1211904 ASKM-0000351, EAF HMN1211904 ASKM-0000351, EAF HMN1211904 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012 at Inactivated, PN HUMANPLK2-012 9/2023 9/2023 9/2023	B2 2024 D2 2024 D1 2024 D1 2024 D1 2024 D2 2024 D2 2024 D1 2024 D2 2024 D3 2024 D3 2024 D3 2024 D3 2024 D3	H16_121031_IQX_01_HR007629 H16_121031_IQX_01_HR007629	9,82,HumanSerum,04,13 9,02,HumanSerum,06,15 9,62,HumanPlasma,01,16 9,72,HumanPlasma,02,17 9,02,HumanPlasma,02,18 9,71,SPQC,19 9,01,QCL0w,20 9,01,QCL0w,20 9,01,QL1QH19,12 9,01,QL19,12 9,01,	2 3	40	tion			80	

"Data Check" Acceptance Criteria




The Most Common and Tedious Problem In Targeted Metabolomics is Peak Assignment for Closely-Eluting, Isobaric Compounds







No Targeted Analysis Software is Immune, Including Skyline



No Targeted Analysis Software is Immune, Including Skyline



The Mis-assignments Are Made Largely for Two Simple Reasons




Skyline has No "Knowledge" of:

1. Relative elution time of analytes2. Whether or not a peak has alreadybeen assigned to another analyte




How we interact with Skyline (Metabolite Quantification)




×908 devices


³Munkres, J. Journal of the Soc. for Ind. and Appl. Math. **1957** 5(1):32–38

Start by adopting the iRT Approach for microchip CZE



20





Approach for Comparison of KM Algo versus Skyline

Goals


- > Benchmark KM algo performance in a relevant complex dataset
- > Understand where performing well and where needs work
- Approach
 - > ZipChip ACE was run on a set of 52 Bioreactor media samples plus standards and QCs
 - > Import Data into Skyline automatically using the ACE App
 - > Compare the results of default Skyline processing to 908 Algo post-processing

Method For Comparison

- > Compared the Apex Time for the "Gold Standard" curated dataset against Skyline Default and 908 Algo approaches.
- > Selection was considered "correct" if retention time of that selected was within 1% of gold standard peak selection




Metric For Comparison, Fraction "Correct" In Both Cases





Metabolite Count, In Order of Fractional Improvement


KM Algorithm is solving some time-intensive assignment problems



Molecule List Name	Molecule Name	% Correct Auto	% Correct 908AI	Improvement %
cylcarnitine	Valerylcarnitine (C5)	19.7%	88.9%	69.2%
Dipeptide	Histidinyl-Valine	29.4%	100.0%	70.6%
Polyamine	N-ACETYLPUTRESCINE	5.9%	77.3%	71.4%
Vitamin	BETAINE	19.1%	91.2%	72.19
Noncanonical AA	5-Methoxytryptophan	11.8%	87.5%	75.7%
IS	13C6/15N L-Leucine (Leu)	23.5%	100.0%	76.5%
CanonicalAA	ISOLEUCINE	23.5%	100.0%	76.5%
Dipeptide	Alanylglutamic acid	8.8%	87.5%	78.7%
Noncanonical AA	2-Phenylglycine	20.6%	100.0%	79.4%
Dipeptide	Lysyl-Leucine	17.9%	97.7%	79.8%
Purine/Pyrimidine	3-METHYLADENINE	16.2%	97.9%	81.7%
Noncanonical AA	Homo-L-arginine	6.3%	89.1%	82.8%
Noncanonical AA	L-Alloisoleucine	5.9%	90.3%	84.4%
Other	5-AMINOPENTANOATE	0.0%	86.7%	86.7%
Noncanonical AA	CIS-4-HYDROXY-D-PROLINE	5.9%	93.7%	87.8%
Noncanonical AA	BETA-ALANINE	0.0%	89.7%	89.7%
Noncanonical AA	ALLOTHREONINE	0.0%	91.7%	91.7%
Dipeptide	Glycyl-Glycine	3.0%	94.7%	91.7%
Noncanonical AA	HOMOSERINE	4.4%	96.8%	92.4%
Dipeptide	Alanyl-Alanine	7.5%	100.0%	92.5%
CanonicalAA	CITRULLINE	5.9%	100.0%	94.19
Dipeptide	N-Methyl-L-proline	4.4%	100.0%	95.6%
Dipeptide	L-Phenylalanyl-L-proline-2	4.4%	100.0%	95.6%
Noncanonical AA	N-METHYLASPARTATE	1.5%	100.0%	98.5%
Dipeptide	Valyl-Glycine	1.5%	100.0%	98.5%
Dipeptide	Threoninyl-Leucine	1.5%	100.0%	98.5%
Dipeptide	Glycylvaline	0.0%	100.0%	100.09
Dipeptide	Glycyl-Glutamate	0.0%	100.0%	100.09











KM Algorithm needs 'tuning' for some cases




Molecule List Name	Molecule Name	%Correct	%Correct	Improvement	
		Auto	908AI	%	
Dipeptide	epsilon-(gamma-Glutamyl)lysine	98.5%	9.3%	-89.2%	
Dipeptide	N2-gamma-Glutamylglutamine	83.8%	0.0%	-83.8%	
Vitamin	NICOTINAMIDE	90.9%	20.0%	-70.9%	
Sugar	GLUCOSAMINE	88.2%	20.3%	-67.9%	
Other	OPHTHALMATE	60.3%	0.0%	-60.3%	
Purine/Pyrimidine	DEOXYCYTIDINE	82.4%	25.8%	-56.5%	
Redox	GLUTATHIONE REDUCED	95.6%	45.8%	-49.8%	
Noncanonical AA	N,N-DIMETHYLARGININE	88.2%	42.2%	-46.0%	
Neurotransmitter/Modulat	ACETYLCHOLINE	51.5%	7.1%	-44.3%	
IS	2H9-Isovalerylcarnitine (C5)	100.0%	58.8%	-41.2%	
IS	2H9-Carnitine (CN)	100.0%	66.2%	-33.8%	

Nonlinear iMT calibration



Noise filtering if # peaks > # targets



26



Conclusions and Future Directions

- Skyline provides a powerful tool to "build from" for commercial solutions
- KM algorithm has general applicability in quantitative mass spec
- We plan to publish and open-source our algo solution
- If you'd like to work with us or hear more, please contact me! <u>wthompson@908devices.com</u>
 THANK YOU!

Booth 159 MP405

TP423





Extra slides

Metabolomics with ZipChip (microchip CZE-MS)


KIT

HARDWARE

SOFTWARE



Reagents/Consumables





ZipChip Interface, Separation Chip (908 Devices) and Orbitrap MS (ThermoFisher)

